Häufiger Konsum von nicht-medizinischem Cannabis

Zusammenfassung

Der nicht-medizinische Cannabiskonsum (Freizeitkonsum) ist besonders unter den jungen Erwachsenen weit verbreitet. Vor dem Hintergrund der laufenden Legalisierungsdebatte sollen körperliche und psychosoziale Begleitbeschwerden des regelmäßigen nicht-medizinischen Cannabiskonsums betrachtet werden. Die gesundheitlichen Folgen erscheinen umso ausgeprägter, je früher der regelmäßige Cannabiskonsum in der Individualentwicklung begonnen hat. Cannabiskonsumenten nehmen zunehmend medizinische Hilfen in Anspruch. Körperliche Begleitbeschwerden wie chronische Bronchitis, zyklische Hyperemesis und Fertilitätsstörungen sind in der Regel reversibel. Auch die oft stark beeinträchtigenden psychischen und kognitiven Begleitbeschwerden reagieren mit hohen Effektstärken (Cohen’s d 0,7 –1,4) auf eine stationäre qualifizierte Entgiftung. Die Schwere der Cannabisabhängigkeit profitiert nachhaltig von psychotherapeutischen und psychosozialen Verfahren (Cohen’s d 0,5–1,2). Aktuell wird das Gesundheitsrisiko durch nicht-medizinisches Cannabis von Suchtexperten deutlich hinter dem durch Tabak oder Alkohol eingeordnet.

Abstract

The non-medical (recreational) use of cannabis is common particularly among young adults. In light of the ongoing legalization debate the clinical impact of physical and psychosocial consequences of regular recreational cannabis consumption should be presented. Health consequences appear to be more pronounced the earlier the regular recreational cannabis use had been started in the individual’s development. There is an increasing demand from recreational cannabis users for medical treatment of cannabis-related complaints including the cannabis withdrawal syndrome. Physical sequelae such as chronic bronchitis, cyclical hyperemesis and fertility problems are usually reversible along with abstinence. The often debilitating cannabis-related mental and cognitive complaints respond on a qualified inpatient detoxification treatment with high effect sizes (Cohen’s d 0.7 –1.4). The severity of the cannabis addiction benefits sustainably from psychotherapeutic approaches and individual psychosocial counseling (Cohen’s d 0,5–1,2). Currently, the actual health hazard of recreational cannabis use was evaluated by addiction experts to be significantly lower than that of tobacco or alcohol use.

Schlüsselwörter

Cannabis - körperliche Beschwerden - psychosoziale Beschwerden - Entgiftungsbehandlung

Keywords

recreational cannabis - physical harm - psychosocial harm - detoxification treatment

• Literatur

• 1 Rumpf HJ, Hoch E, Thomasius R, Havemann-Reinecke U. Stellungnahme zur Legalisierungsdebatte des nicht-medizinischen Cannabiskonsums (beschlossen vom Vorstand der DG-Sucht am 09.07.2015). Im Internet: www.dg-sucht.de/fileadmin/user_upload/pdf/stellungnahmen/Stellungnahme_Legalisierungsdebatte_Cannabis_DG-Sucht.pdf letzter Zugriff: 05.09.15
• 2 Gerich ME, Isfort RW, Brimhall B et al. Medical marijuana for digestive disorders: high time to prescribe?. Am J Gastroenterol 2015; 110: 208-14
• 3 Bonnet U, Scherbaum N. Cannabisbezogene Störungen. Teil II: Psychiatrische und somatische Folgestörungen und Komorbiditäten. Fortschr Neurol Psychiat 2010; 78: 1-11
• 4 Hoch E, Bonnet U, Thomasius R et al. Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int 2015; 112: 271-278
• 5 Karila L, Roux P, Rolland B et al. Acute and long-term effects of cannabis use: a review. Curr Pharm Des 2014; 20: 4112-4118
• 6 Braun B, Künzel J, Brand H. Jahresstatistik 2013 der professionellen Suchtkrankenhilfe. In: Jahrbuch Sucht 2015. Deutsche Hauptstelle für Suchtfragen e. V., Hrsg. Lengerich: Pabst; 2015: 214-240
• 7 MacCoun RJ, Mello MM. Half-baked – the retail promotion of marijuana edibles. N Engl J Med 2015; 372: 989-991
• 8 Volkow ND, Baler RD, Compton WM et al. Adverse health effects of marijuana use. N Engl J Med 2014; 370: 2219-2227
• 9 Ghosh TS, Van Dyke M, Maffey A et al. Medical marijuana’s public health lessons – implications for retail marijuana in Colorado. N Engl J Med 2015; 372: 991-993
• 10 Salomonsen-Sautel S, Min SJ, Sakai JT et al. Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado. Drug Alcohol Depend 2014; 140: 137-144
• 11 Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr 2013; 167: 630-633
• 12 Bachhuber MA, Saloner B, Cunningham CO et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 2014; 174: 1668-1673
• 13 Woodward MR, Harper DG, Stolyar A et al. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry 2014; 22: 415-419
• 14 Bundeszentrale für gesundheitliche Aufklärung Der Cannabiskonsum Jugendlicher und junger Erwachsener in Deutschland 2012. Ergebnisse einer aktuellen Repräsentativbefragung und Trends. Im Internet: www.slsev.de/uploads/media/Tabakkonsum_Jugendlicher_2012.pdf letzter Zugriff: 02.12.15
• 15 Pabst A, Kraus L, Gomes de Matos E et al. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 2013; 59: 321-331
• 16 Bonnet U, Scherbaum N. Cannabisbezogene Störungen. Teil I: Pharmakologie, Epidemiologie und Therapieverfahren. Fortschr Neurol Psychiatr 2010; 78: 297-302
• 17 Farmer RF, Kosty DB, Seeley JR et al. Natural course of cannabis use disorders. Psychol Med 2015; 45: 63-72
• 18 Di Forti M, Marconi A, Carra E et al. Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015; DOI: 10. 1016/S2215-0366(14)00117–5
• 19 Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 2015; 45: 3181-3189
• 20 Fontes MA, Bolla KI, Cunha PJ et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 2011; 198: 442-427
• 21 Meier MH, Caspi A, Ambler A et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109: E2657-664
• 22 Hurd YL, Michaelides M, Miller ML et al. Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology 2014; 76 Pt B: 416-424
• 23 Cougle JR, Hakes JK, Macatee RJ et al. Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiatr Res 2015; 66–67: 135-141
• 24 Bonnet U, Borda T, Scherbaum N, Specka M. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum. Drug Alcohol Depend 2015; 155: 302-306
• 25 Danielsson AK, Falkstedt D, Hemmingsson T et al. Cannabis use among Swedish men in adolescence and the risk of adverse life course outcomes: results from a 20 year-follow-up study. Addiction 2015; 110: 1794-1802
• 26 Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 2014; 113: 187-190
• 27 Conner SN, Carter EB, Tuuli MG et al. Maternal marijuana use and neonatal morbidity. Am J Obstet Gynecol 2015; 213: 422.e1-4
• 28 Huizink AC. Prenatal cannabis exposure and infant outcomes: overview of studies. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52: 45-52
• 29 Nicolson SE, Denysenko L, Mulcare JL et al. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics 2012; 53: 212-219
• 30 Tarantino G, Citro V, Finelli C. Recreational drugs: a new health hazard for patients with concomitant chronic liver diseases. J Gastrointestin Liver Dis 2014; 23: 79-84
• 31 Hancox RJ, Shin HH, Gray AR et al. Effects of quitting cannabis on respiratory symptoms. Eur Respir J 2015; 46: 80-87
• 32 Rooke SE, Norberg MM, Copeland J et al. Health outcomes associated with long-term regular cannabis and tobacco smoking. Addict Behav 2013; 38: 2207-2213
• 33 Muniyappa R, Sable S, Ouwerkerk R et al. Metabolic effects of chronic cannabis smoking. Diabetes Care 2013; 36: 2415-2422
• 34 McLaren J, Swift W, Dillon P et al. Cannabis potency and contamination: a review of the literature. Addiction 2008; 103: 1100-1109
• 35 Rodríguez-Castro CE, Alkhateeb H, Elfar A et al. Recurrent myopericarditis as a complication of Marijuana use. Am J Case Rep 2014; 15: 60-62
• 36 Bonnet U, Mahler H. Synthetische Cannabinoide: Verbreitung, Suchtbiologie & aktuelle Perspektive der persönlichen Gesundheitsgefährdung. Fortschr Neurol Psychiatr 2015; Apr 83: 221-231
• 37 Hartung B, Kauferstein S, Ritz-Timme S et al. Sudden unexpected death under acute influence of cannabis. Forensic Sci Int 2014; 237: e11-13
• 38 Nutt DJ, King LA, Phillips LD. Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376: 1558-1565
• 39 van Amsterdam J, Opperhuizen A, Koeter M et al. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res 2010; 16: 202-207
• 40 Degenhardt L, Whiteford HA, Ferrari AJ et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564-1574
• 41 Bonnet U, Specka M, Stratmann U et al. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. Drug Alcohol Depend 2014; 143: 189-197
• 42 Licata M, Verri P, Beduschi G. Delta9 THC content in illicit cannabis products over the period 1997–2004 (first four months). Ann Ist Super Sanita 2005; 41: 483-485
• 43 Mahler H Persönliche Mitteilung von Dr. H. Mahler, kriminaltechnisches Institut des Landeskriminalamt NRW Düsseldorf: 2015
• 44 Swift W, Wong A, Li KM et al. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 2013; 8: e70052-0
• 45 Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999; 94: 1311-1322
• 46 Dilling H, Mombour W, Schmidt MH. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Diagnostische Kriterien für Forschung und Praxis Bern; Huber: 2004
• 47 American Psychiatric Association (APA) Diagnostic and statistical manual of mental disorders. 5. Aufl. (DSM-5TM). Washington, DC: APA; 2013
• 48 Holzbach R, Behrendt K, Maylath E et al. Positionspapier zum stationären qualifizierten Entzug von Cannabispatienten. Suchtmed 2006; 8: 9-14
• 49 Balter RE, Cooper ZD, Haney M. Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep 2014; 1: 137-143
• 50 Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatr Clin North Am 2012; 35: 309-326
• 51 Cohen J. Statistical power for the behavioral sciences. New York: Academic Press; 1988
• 52 Cooper K, Chatters R, Kaltenthaler E et al. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess 2015; 19: 1-130
• 53 Zumdick S, Schneider U, Leweke M et al. Studienlage zur Behandlung der Cannabisabhängigkeit. Fortschr Neurol Psychiatr 2006; 74: 211-225
• 54 Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychology 1994; 62: 92-99
• 55 Hoch E, Bühringer G, Pixa A et al. CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. Drug Alcohol Depend 2014; 134: 185-193
• 56 Bonnet U, Stratmann U, Isbruch K. Keine Opiate gegen das Cannabis-Hyperemesis-Syndrom. Dtsch med Wochenschr 2014; 139: 375-377
• 57 Alshaarawy O, Anthony JC. Cannabis Smoking and Diabetes Mellitus: Results from Meta-analysis with Eight Independent Replication Samples. Epidemiology 2015; 26 (4) 597-600